ARTICLE | Clinical News
Oliglow: Began Phase I/II trial
December 3, 2001 8:00 AM UTC
Angiogene Inc., Montreal, Quebec Product: Oliglow Business: Cardiovascular Therapeutic category: Cell proliferation Target: Arterial smooth muscle cells Description: DNA beta-emitting isotope comple...